The New England journal of medicine, 2018-05, Vol.378 (22), p.2078-2092
- Gandhi, Leena
- Rodríguez-Abreu, Delvys
- Gadgeel, Shirish
- Esteban, Emilio
- Felip, Enriqueta
- De Angelis, Flávia
- Domine, Manuel
- Clingan, Philip
- Hochmair, Maximilian J
- Powell, Steven F
- Cheng, Susanna Y.-S
- Bischoff, Helge G
- Peled, Nir
- Grossi, Francesco
- Jennens, Ross R
- Reck, Martin
- Hui, Rina
- Garon, Edward B
- Boyer, Michael
- Rubio-Viqueira, Belén
- Novello, Silvia
- Kurata, Takayasu
- Gray, Jhanelle E
- Vida, John
- Wei, Ziwen
- Yang, Jing
- Raftopoulos, Harry
- Pietanza, M. Catherine
- Garassino, Marina C
2018
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Gandhi, Leena
- Rodríguez-Abreu, Delvys
- Gadgeel, Shirish
- Esteban, Emilio
- Felip, Enriqueta
- De Angelis, Flávia
- Domine, Manuel
- Clingan, Philip
- Hochmair, Maximilian J
- Powell, Steven F
- Cheng, Susanna Y.-S
- Bischoff, Helge G
- Peled, Nir
- Grossi, Francesco
- Jennens, Ross R
- Reck, Martin
- Hui, Rina
- Garon, Edward B
- Boyer, Michael
- Rubio-Viqueira, Belén
- Novello, Silvia
- Kurata, Takayasu
- Gray, Jhanelle E
- Vida, John
- Wei, Ziwen
- Yang, Jing
- Raftopoulos, Harry
- Pietanza, M. Catherine
- Garassino, Marina C
- Titel
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- Ist Teil von
- The New England journal of medicine, 2018-05, Vol.378 (22), p.2078-2092
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2018
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- The addition of pembrolizumab to chemotherapy for metastatic lung cancer without EGFR or ALK mutations resulted in better progression-free and overall survival than chemotherapy alone. Immune-related adverse effects were more common with the combination.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1801005Titel-ID: cdi_proquest_miscellaneous_2025801116
- Format
- –
- Schlagworte
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized - adverse effects, Antibodies, Monoclonal, Humanized - therapeutic use, Antineoplastic Agents, Immunological - adverse effects, Antineoplastic Agents, Immunological - therapeutic use, Antineoplastic Combined Chemotherapy Protocols - adverse effects, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Apoptosis, Cancer therapies, Carcinoma, Non-Small-Cell Lung - drug therapy, Carcinoma, Non-Small-Cell Lung - genetics, Carcinoma, Non-Small-Cell Lung - mortality, Carcinoma, Non-Small-Cell Lung - secondary, Chemotherapy, Cytotoxicity, Death, Disease-Free Survival, Double-Blind Method, Epidermal growth factor receptors, Female, Follow-Up Studies, Hospitals, Humans, Immunotherapy, Kaplan-Meier Estimate, Laboratories, Lung cancer, Lung Neoplasms - drug therapy, Lung Neoplasms - genetics, Lung Neoplasms - mortality, Lung Neoplasms - pathology, Male, Metastases, Metastasis, Middle Aged, Monoclonal antibodies, Mutation, Non-small cell lung carcinoma, Patients, PD-L1 protein, Pembrolizumab, Platinum, Response rates, Targeted cancer therapy